CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junctio… Read more
CStone Pharmaceuticals (CSPHF) - Total Assets
Latest total assets as of June 2025: $1.19 Billion USD
Based on the latest financial reports, CStone Pharmaceuticals (CSPHF) holds total assets worth $1.19 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CStone Pharmaceuticals - Total Assets Trend (2016–2024)
This chart illustrates how CStone Pharmaceuticals’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CStone Pharmaceuticals - Asset Composition Analysis
Current Asset Composition (December 2024)
CStone Pharmaceuticals's total assets of $1.19 Billion consist of 78.2% current assets and 21.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.8% |
| Accounts Receivable | $130.88 Million | 9.4% |
| Inventory | $286.10 Million | 20.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $161.37 Million | 11.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how CStone Pharmaceuticals's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CStone Pharmaceuticals's current assets represent 78.2% of total assets in 2024, a decrease from 99.8% in 2016.
- Cash Position: Cash and equivalents constituted 27.8% of total assets in 2024, up from 7.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 20.5% of total assets.
CStone Pharmaceuticals Competitors by Total Assets
Key competitors of CStone Pharmaceuticals based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
CStone Pharmaceuticals - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - CStone Pharmaceuticals generates 0.29x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - CStone Pharmaceuticals is currently not profitable relative to its asset base.
CStone Pharmaceuticals - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.44 | 1.71 | 4.91 |
| Quick Ratio | 1.20 | 1.45 | 4.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $275.69 Million | $ 505.08 Million | $ 2.85 Billion |
CStone Pharmaceuticals - Advanced Valuation Insights
This section examines the relationship between CStone Pharmaceuticals's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.54 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | -16.2% |
| Total Assets | $1.39 Billion |
| Market Capitalization | $497.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values CStone Pharmaceuticals's assets below their book value (0.36 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: CStone Pharmaceuticals's assets decreased by 16.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CStone Pharmaceuticals (2016–2024)
The table below shows the annual total assets of CStone Pharmaceuticals from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.39 Billion | -16.16% |
| 2023-12-31 | $1.66 Billion | +1.44% |
| 2022-12-31 | $1.64 Billion | -27.87% |
| 2021-12-31 | $2.27 Billion | -39.63% |
| 2020-12-31 | $3.76 Billion | +27.52% |
| 2019-12-31 | $2.95 Billion | +80.79% |
| 2018-12-31 | $1.63 Billion | +189.24% |
| 2017-12-31 | $564.28 Million | -31.70% |
| 2016-12-31 | $826.14 Million | -- |